Dual Inhibition of MET and VEGF Signaling With Cabozantinib Blocks Tumor ... - MarketWatch (press release)

onesawava.wordpress.com

Dual Inhibition of MET and VEGF Signaling With Cabozantinib Blocks Tumor ... MarketWatch (press release) SOUTH SAN FRANCISCO, Calif., Feb 24, 2012 (BUSINESS WIRE) -- Exelixis, Inc. (NASDAQ:EXEL) today announced the company's lead compound, cabozantinib, is highlighted in a new peer-reviewed publication demonstrating that simultaneous inhibition of MET and ... and more »